NCT00382668View on ClinicalTrials.gov

A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Liver Diseases
Interventions
DRUG

Dasatinib

Tablets, Oral, 50 mg, once daily, for one day

DRUG

Dasatinib

Tablets, Oral, 20 mg, once daily for one day

DRUG

Dasatinib

Tablets, Oral, 70 mg, once daily for one day

Trial Locations (4)

32809

Orlando Clinical Research Center, Orlando

33025

Comprehensive Phase One, Miramar

33136

University Of Miami, Miami

37920

New Orleans Center For Clinical Research, Knoxville

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00382668 - A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug | Biotech Hunter | Biotech Hunter